Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms
Journal of Medicinal Chemistry · 09.10.2025 · 68 (19) · 20536-20560
DOI: 10.1021/acs.jmedchem.5c01736 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 26.09.2025. Verfasst von Farman M Abbasi und 12 weiteren Autor:innen. Beteiligte Einrichtung: Medicinal and Process Chemistry Division, CSIR-Central Drug Research Institute, Sector 10, Jankipuram Extension, Lucknow 226031, Uttar Pradesh, India. Hauptthemen laut MEDLINE: Cyclic Nucleotide Phosphodiesterases, Type 1, Osteoporosis, Postmenopausal, Bone Density Conservation Agents, Drug Discovery. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 63 Literaturangaben. Gefördert von: Department of Biotechnology, Ministry of Science and Technology, India, Department of Science and Technology, Ministry of Science and Technology, India, Council of Scientific and Industrial Research, India.
Abstract (Originalsprache)
Postmenopausal osteoporosis (PMO) is characterized by an imbalance in bone remodeling with increased osteoclast and decreased osteoblast activity, leading to bone loss and higher fracture risk. Current treatments, such as teriparatide, boost bone formation but also elevate resorption, limiting their long-term effectiveness. We discovered 3-butyl-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4(3H)-one (5cc), an orally active phosphodiesterase-1 (PDE1) inhibitor aimed at restoring this balance. 5cc enhances osteoblast differentiation assessed by increased alkaline phosphatase activity, Runx2 expression, and mineralized nodule formation. Additionally, it inhibited osteoclastogenesis by suppressing the RANKL/OPG ratio, modulating Eph-Ephrin signaling, and attenuating IL-1β-induced ROS and NF-κB activation in vitro. In ovariectomized mice, 5cc administration (5 mg/kg) improved the trabecular microarchitecture, bone mineral density, and strength, at levels comparable to teriparatide, while significantly reducing bone resorption markers. With 13.57% oral bioavailability and selectivity for PDE1A1 (32% inhibition at 500 nM), 5cc offers an innovative therapeutic candidate for PMO with a dual anabolic-antiresorptive profile and oral efficacy, warranting further clinical development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Medicinal and Process Chemistry Division, CSIR-Central Drug Research Institute, Sector 10, Jankipuram Extension, Lucknow 226031, Uttar Pradesh, India.
- Academy of Scientific and Innovative Research (AcSIR), Ghaziabad 201002, Uttar Pradesh, India.
- Endocrinology Division and Centre for Research in ASTHI, CSIR-Central Drug Research Institute, Sector 10, Jankipuram Extension, Lucknow 226031, Uttar Pradesh, India.
- Biochemistry and Structural Biology Division, CSIR-Central Drug Research Institute, Sector 10, Jankipuram Extension, Lucknow 226031, Uttar Pradesh, India.
- Pharmacokinetics Division, CSIR-Central Drug Research Institute, Sector 10, Jankipuram Extension, Lucknow 226031, Uttar Pradesh, India.
ORCID-Profile: Shubham K Talware, Jiaur R Gayen, Sanjay Batra
Förderung
- Department of Biotechnology, Ministry of Science and Technology, India
- Department of Science and Technology, Ministry of Science and Technology, India
- Council of Scientific and Industrial Research, India
- University Grants Commission
- Central Drug Research Institute
Zitieren
APA
Abbasi, F. M., Porwal, K., Pal, S., Sharma, S., Sadhukhan, S., Rajput, S., Kulkarni, C., Talware, S. K., Siddiqi, M. I., Chauhan, D., Gayen, J. R., Chattopadhyay, N., & Batra, S. (2025). Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms. Journal of Medicinal Chemistry, 68(19), 20536-20560. https://doi.org/10.1021/acs.jmedchem.5c01736
Vancouver
Abbasi FM, Porwal K, Pal S, Sharma S, Sadhukhan S, Rajput S, et al. Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms. Journal of Medicinal Chemistry. 2025;68(19):20536-20560. doi:10.1021/acs.jmedchem.5c01736
BibTeX
@article{Abbasi2025,
author = {Abbasi, Farman M and Porwal, Konica and Pal, Subhashis and Sharma, Shivani and Sadhukhan, Sreyanko and Rajput, Swati and Kulkarni, Chirag and Talware, Shubham K and Siddiqi, Mohammad I and Chauhan, Divya and Gayen, Jiaur R and Chattopadhyay, Naibedya and Batra, Sanjay},
title = {Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms},
journal = {Journal of Medicinal Chemistry},
year = {2025},
volume = {68},
number = {19},
pages = {20536--20560},
doi = {10.1021/acs.jmedchem.5c01736}
}
EUVIMED